GLP-1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications

More on GLP-1 receptor agonists

• Diabetes, Obesity & Metabolism·8 Oct 2026

  Diabetes drug class linked to slightly less frailty progression

  

• Diabetes & Vascular Disease Research·4 Oct 2026

  SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs

• Diabetes, Obesity & Metabolism·4 Oct 2026

  GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk

• Neurology Genetics·4 Oct 2026

  GLP-1 receptor agonists link to lower stroke and Alzheimer risk